Docetaxel and Irinotecan in Gastric Cancer

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The primary end point is response rate. Secondary end points are toxicity, PFS and OS.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Menoufia University
• Treatments: Docetaxel; Irinotecan

Criteria

Inclusion Criteria:

• Histopathological evidence of adenocarcinoma of the stomach

• Metastatic disease or locally advanced non-resectable disease

• Patients who received only one line of treatment

• Performance status 0,1,2 as per ECOG scoring system

Exclusion Criteria:

• Patients who received docetaxel or irinotecan before recruitment to this study

• Multiple comorbid conditions

• Liver or kidney impairment

• Severe cachexia (sarcopenia)